Zevra Therapeutics (ZVRA) Competitors $9.30 -0.06 (-0.64%) Closing price 04:00 PM EasternExtended Trading$9.37 +0.07 (+0.75%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. IBRX, OCUL, IRON, BLTE, RXRX, CGON, ANIP, SRPT, MESO, and ADPTShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include ImmunityBio (IBRX), Ocular Therapeutix (OCUL), Disc Medicine (IRON), Belite Bio (BLTE), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), Sarepta Therapeutics (SRPT), Mesoblast (MESO), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors ImmunityBio Ocular Therapeutix Disc Medicine Belite Bio Recursion Pharmaceuticals CG Oncology ANI Pharmaceuticals Sarepta Therapeutics Mesoblast Adaptive Biotechnologies ImmunityBio (NASDAQ:IBRX) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability. Which has more volatility & risk, IBRX or ZVRA? ImmunityBio has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Do analysts rate IBRX or ZVRA? ImmunityBio presently has a consensus target price of $10.75, suggesting a potential upside of 361.37%. Zevra Therapeutics has a consensus target price of $23.71, suggesting a potential upside of 154.99%. Given ImmunityBio's stronger consensus rating and higher possible upside, equities research analysts plainly believe ImmunityBio is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is IBRX or ZVRA more profitable? Zevra Therapeutics has a net margin of 4.33% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-648.57% N/A -113.86% Zevra Therapeutics 4.33%-112.40%-37.67% Which has better valuation and earnings, IBRX or ZVRA? Zevra Therapeutics has higher revenue and earnings than ImmunityBio. Zevra Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M149.42-$413.56M-$0.48-4.85Zevra Therapeutics$23.61M22.11-$105.51M-$0.21-44.29 Does the media refer more to IBRX or ZVRA? In the previous week, ImmunityBio had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for ImmunityBio and 6 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.80 beat ImmunityBio's score of 0.52 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in IBRX or ZVRA? 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 76.8% of ImmunityBio shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryZevra Therapeutics beats ImmunityBio on 9 of the 16 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$525.42M$2.51B$5.78B$9.80BDividend YieldN/A1.68%3.95%4.02%P/E Ratio-44.2922.8231.2626.59Price / Sales22.11733.81464.64173.43Price / CashN/A177.0937.7359.36Price / Book4.456.1810.046.68Net Income-$105.51M$32.94M$3.27B$265.59M7 Day Performance-2.21%0.99%3.17%3.42%1 Month Performance-13.97%1.69%4.34%1.09%1 Year Performance28.10%11.44%44.12%23.84% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics3.3853 of 5 stars$9.30-0.6%$23.71+155.0%+29.8%$525.42M$23.61M-44.2920IBRXImmunityBio2.251 of 5 stars$2.31+3.1%$10.75+365.4%-44.2%$2.12B$14.74M-4.81590News CoverageAnalyst ForecastOCULOcular Therapeutix4.0096 of 5 stars$12.30+1.4%$17.20+39.8%+36.3%$2.11B$63.72M-9.61230Positive NewsInsider TradeIRONDisc Medicine3.6541 of 5 stars$60.35+1.0%$98.30+62.9%+21.2%$2.08BN/A-13.5030News CoverageInsider TradeBLTEBelite Bio3.0079 of 5 stars$64.40-1.2%$96.67+50.1%+31.2%$2.08BN/A-41.5510Positive NewsRXRXRecursion Pharmaceuticals1.9803 of 5 stars$4.94+3.3%$7.00+41.7%-35.7%$2.08B$58.84M-2.78400CGONCG Oncology1.2461 of 5 stars$26.92+3.6%$55.27+105.3%-27.5%$1.98B$1.14M-15.2161Positive NewsANIPANI Pharmaceuticals3.2542 of 5 stars$91.01-0.1%$84.75-6.9%+45.3%$1.98B$614.38M-118.19600Insider TradeSRPTSarepta Therapeutics4.553 of 5 stars$20.22+0.8%$43.50+115.1%-87.2%$1.96B$1.90B-23.241,372Analyst ForecastMESOMesoblast2.1926 of 5 stars$15.81+4.2%$18.00+13.9%+153.5%$1.94B$5.90M0.0080News CoverageADPTAdaptive Biotechnologies2.5271 of 5 stars$13.00+2.9%$12.38-4.8%+179.5%$1.92B$178.96M-15.85790 Related Companies and Tools Related Companies ImmunityBio Alternatives Ocular Therapeutix Alternatives Disc Medicine Alternatives Belite Bio Alternatives Recursion Pharmaceuticals Alternatives CG Oncology Alternatives ANI Pharmaceuticals Alternatives Sarepta Therapeutics Alternatives Mesoblast Alternatives Adaptive Biotechnologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access